XML 45 R37.htm IDEA: XBRL DOCUMENT
v3.25.3

Fair Value - Additional Information (Details) |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
May 08, 2025 USD ($) $ / shares | Sep. 30, 2024 USD ($) | Jul. 31, 2023 USD ($) Installment | Apr. 07, 2022 | Oct. 31, 2024 USD ($) | Jul. 31, 2024 USD ($) | Apr. 30, 2024 USD ($) Installment | Apr. 30, 2022 USD ($) Installment | Jan. 31, 2016 USD ($) shares | Sep. 30, 2025 USD ($) | Sep. 30, 2024 USD ($) | Sep. 30, 2025 USD ($) | Sep. 30, 2024 USD ($) | Dec. 31, 2018 USD ($) Installment shares | Feb. 28, 2025 $ / shares | Mar. 31, 2024 $ / shares | Dec. 15, 2023 USD ($) | Nov. 21, 2022 shares
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount withdrawn |  |  |  |  |  |  |  |  |  | $ 50,010,000 |  | $ 50,010,000 |  |  |  |  |  |
Change in fair value of warrant liability | $ 200,000 |  |  |  |  |  |  |  |  |  |  | 280,000 |  |  |  |  |  |
Loss on debt extinguishment |  |  |  |  |  |  |  |  |  |  |  |  | $ (248,000) |  |  |  |  |
IPO |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant, exercise price | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 89.04 |  |
Tranche B Loan | Second Amendment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount withdrawn |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000 |
Contingent Consideration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest expense due to passage of time and fixed payment schedule |  |  |  |  |  |  |  |  |  |  | $ 200,000 |  | 1,100,000 |  |  |  |  |
Contingent Consideration | Third Amendment to APA Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  | $ 8,400,000 |  |  |  |  |  |  |  |  |  |  |  |
Warrant Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant issued to purchase shares | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 250,000
Change in fair value of warrant liability |  |  |  |  |  |  |  |  |  | 0 | 0 | (300,000) | 0 |  |  |  |  |
Warrant Liabilities | Tranche C Loan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant, exercise price | $ / shares | $ 8.382 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15.86 |  |  |
Amount withdrawn | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent Value Rights | Series F Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Change in fair value of warrant liability |  |  |  |  |  |  |  |  |  | $ 0 | $ 0 | $ 0 | $ 0 |  |  |  |  |
Percentage of net proceeds |  |  |  |  |  |  |  |  | 15.00% |  |  |  |  |  |  |  |  |
Contingent Value Rights | Series F Preferred Stock | Ficlatuzumab |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent value rights interest rate |  |  |  |  |  |  |  |  | 0.00375% |  |  |  |  |  |  |  |  |
Shares issued | shares |  |  |  |  |  |  |  |  | 3,999 |  |  |  |  |  |  |  |  |
Drug interest rate percentage |  |  |  |  |  |  |  |  | 15.00% |  |  |  |  |  |  |  |  |
Contingent value rights |  |  |  |  |  |  |  |  | $ 500,000 |  |  |  |  |  |  |  |  |
Integrated Diagnostics, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exit fee payment |  | $ 6,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostics, Inc | Contingent Consideration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business acquisition description |  |  |  |  |  |  |  |  |  |  |  | required additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month |  |  |  |  |  |
Business acquisition contingent consideration gross margin target |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,000,000 |  |  |  |
Business acquisition contingent consideration gross margin target period |  |  |  |  |  |  |  |  |  |  |  |  |  | 7 years |  |  |  |
Integrated Diagnostics, Inc | Contingent Consideration | Third Amendment to APA Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration number of installments | Installment |  |  | 3 |  |  |  | 1 | 5 |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  | $ 3,000,000 |  |  |  | $ 5,000,000 | $ 2,000,000 |  |  |  |  |  |  |  |  |  |
Percentage of interest on installment payments |  |  |  | 10.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exit fee payment |  |  |  |  | $ 6,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostics, Inc | Common Stock | Contingent Consideration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business acquisition description |  |  |  |  |  |  |  |  |  |  |  | If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million. |  |  |  |  |  |
Contingent consideration shares | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,520,108 |  |  |  |
Contingent consideration number of installments | Installment |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 |  |  |  |
Contingent consideration arrangements, common shares, redemption amount |  |  |  |  |  |  |  |  |  |  |  | $ 4,600,000 |  | $ 37,000,000 |  |  |  |
Repayments of debt |  |  |  |  |  |  |  |  |  |  |  | 9,300,000 |  |  |  |  |  |
Business combination contingent consideration final payment |  |  |  |  |  |  |  |  |  |  |  | $ 37,000,000 |  |  |  |  |  |
Contingent consideration cash payment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 37,000,000 |  |  |  |
Investment, Type [Extensible Enumeration] |  |  |  |  |  |  |  |  |  |  |  |  |  | Repurchase [Member] |  |  |  |

X
- Definition Business acquisition contingent consideration gross margin target period. + References No definition available. + Details
Name: | bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod
Namespace Prefix: | bdsx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business acquisition contingent consideration number of installments. + References No definition available. + Details
Name: | bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments
Namespace Prefix: | bdsx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business combination contingent consideration arrangements common shares redemption amount. + References No definition available. + Details
Name: | bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business combination contingent consideration final payment. + References No definition available. + Details
Name: | bdsx_BusinessCombinationContingentConsiderationFinalPayment
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business combination contingent consideration shares. + References No definition available. + Details
Name: | bdsx_BusinessCombinationContingentConsiderationShares
Namespace Prefix: | bdsx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent value rights fair value disclosure. + References No definition available. + Details
Name: | bdsx_ContingentValueRightsFairValueDisclosure
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent value rights interest rate. + References No definition available. + Details
Name: | bdsx_ContingentValueRightsInterestRate
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Drug interest rate percentage. + References No definition available. + Details
Name: | bdsx_DrugInterestRatePercentage
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exit fee payment. + References No definition available. + Details
Name: | bdsx_ExitFeePayment
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Interest expense due to passage of time and fixed payment schedule. + References No definition available. + Details
Name: | bdsx_InterestExpenseDueToPassageOfTimeAndFixedPaymentSchedule
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment. + References No definition available. + Details
Name: | bdsx_MilestonePayment
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of interest on contingent consideration. + References No definition available. + Details
Name: | bdsx_PercentageOfInterestOnContingentConsideration
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of net proceeds. + References No definition available. + Details
Name: | bdsx_PercentageOfNetProceeds
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of acquiree in business combination. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 38 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_CashAcquiredFromAcquisition
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + References No definition available. + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_FairValueAdjustmentOfWarrants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details
Name: | us-gaap_GainsLossesOnExtinguishmentOfDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column C)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2 + Details
Name: | us-gaap_InvestmentTypeExtensibleEnumeration
Namespace Prefix: | us-gaap_
Data Type: | enum2:enumerationSetItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details
Name: | us-gaap_LongTermDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_RepaymentsOfDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=bdsx_SecondAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=bdsx_ThirdAmendmentToApaAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentValueRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |